3 Carrascosa JM, Gardeazabal J, Pérez-Ferriols A et al. Consensus document on phototherapy: PUVA therapy and narrow-Band UVB therapy. Actas Dermosifiliogr 2005; 96: 635-658. 4 Hamilton TK. Clinical considerations of efalizumab therapy in patients with psoriasis. Semin Cutan Med Surg 2005; 24: 19-27. 5 Ibbotson SH, Bilsland D, Cox NH et al. An update and guidance on narrowband ultraviolet B phototherapy: a British Photodermatology Group Workshop Report. Br J Dermatol 2004; 151: 283-297. 6 Cather JC, Menter A. Combining traditional agents and biologics for the treatment of psoriasis. Semin Cutan Med Surg 2005; 24: 34-37.(> 80 years), instead of 50-75 years detected in more fair-complexioned populations. 1 However, statistically (chi-square) there was a plateau of detection rates after 60 years in cutaneous horn, actinic cheilitis and Bowen's disease, but not in actinic keratoses (P < 0.0001), solitary keratoacanthomas (P = 0.005) and SCC (P = 0.004). Proportional morbidity might be roughly approximated by prevalence ratios (Table 1, totals). Apart from actinic keratoses only cutaneous horn exceeded the prevalence of SCC. Similarly, in a population-based incidence study of Kauai white residents, 4 the frequency of keratoacanthoma was lower but near to that of SCC and not either greater or many times less, as in other reports. 1